Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6867461 (RG7716) Following Intravitreal Administration in Japanese Patients with Wet Age-Related Macular Degeneration and Diabetic Macular Edema

Trial Profile

A phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6867461 (RG7716) Following Intravitreal Administration in Japanese Patients with Wet Age-Related Macular Degeneration and Diabetic Macular Edema

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Dec 2018

At a glance

  • Drugs Faricimab (Primary)
  • Indications Diabetic macular oedema; Wet age-related macular degeneration
  • Focus Adverse reactions
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 05 Dec 2018 Status changed from active, no longer recruiting to completed.
    • 01 Jun 2018 Status changed from recruiting to active, no longer recruiting.
    • 30 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top